Abstract:Kai Tang, Heng Zhao Fujian Provincial Key Laboratory of Innate Immune Biology, Fujian Normal University, Fujian, People's Republic of China Correspondence: Heng Zhao, Fujian Provincial Key Laboratory of Innate Immune Biology, Fujian Normal University, Fujian, People's Republic of China, Tel +86-17689970104, Email The clinical application of quinolone antibiotics is particularly extensive. In addition to their high efficiency in infectious diseases, the treatment process brings multiple hidden dangers or side effects. In this regard, drug resistance becomes a major challenge and is almost unavoidable in the clinical application of quinolones. Both genetic and phenotypic variations contribute to bacterial survival resistance under antibiotic therapy. This review is focusing on the drug discovery history, compound structure, and bactericidal mechanism of quinolone antibiotics. Recent studies bring a more in-depth insight into the research progress of quinolone antibiotics in the causes of death, drug resistance formation, and closely related SOS response after disease treatment at this stage. Combined with the latest clinical studies, we summarize the clinical application of quinolone antibiotics and further lay a theoretical foundation for the mechanism study of resistant or sensitive bacteria in response to quinolone treatment. Keywords: quinolone antibiotics, disease treatment, SOS response, lethality, bacteria The earliest quinolone antibiotics were discovered in the 1960s. 1 Their basic structures consist of bicyclic skeletons, carboxylic acids, and keto groups at positions 3 and 4, respectively, which are necessary for their pharmacological activity 2,3 (Figure 1). To obtain broad-spectrum antibiotics, the so-called fluoroquinolones (FQs) can be synthesized by introducing fluorine atoms into the chemical structure of quinolone. For instance, norfloxacin was discovered in 1979, followed by a series of fluorine-containing new quinolones that emerged as FQs. And FQs are one of the most widely prescribed broad-spectrum antibiotics and show sufficient antibacterial activity against both Gram-negative and Gram-positive bacteria. 4 Figure 1 Core structure of quinolone antibiotics. ( A ) Six important modification positions include R1, R5, R6, R7, R8, and X for improving the drug activity. X=C defines quinolones and X=N defines naphthenes. ( B ) Each modification position has different effects such as antibacterial, affecting pharmacokinetics, enhancing activity and enzymatic binding. The term quinolone is often used in a general sense to categorize a class of compounds including quinolones, nalididones, quinazolines, isothiazoquinolones, etc. Mechanistically, quinolones can target two basic bacterial enzymes, DNA helicase (topoisomerase II) 5 and DNA topoisomerase IV, 6 both of which contain four subunits (2 GyrA or ParC and 2 GyrB or ParE). The enzymes can transfer one region of double-stranded DNA to another, thereby forming the enzyme-quinolones-DNA complexes. 7–11 Quinolones mainly target helicases and topoisomerases that are critical for regulating the superhelix of genomic DNA in the process of replication and transcription in bacterias. 12,13 These complexes prevent the movement of replication forks and transcriptional complexes in vitro, thereby inhibiting bacterial growth. 14–16 Quinolones capture DNA helicase and DNA topoisomerase IV on DNA in the form of complexes, therefore leading to DNA break. However, their effects can be limited by proteins such as drug-enzyme-DNA complexes that reversibly inhibit DNA replication or fragment bacterial chromosomes. In one pathway, chromosome fragmentation stimulates excessive accumulation of highly toxic reactive oxygen species (ROS)-related compounds that are the main causes of cell death. 17 DNA double-strand break (DSB) is a potentially fatal DNA damage, while FQs contribute to DSB by binding to the active site of type II topoisomerase after DNA cleavage to form a quinolone-enzyme complex that disrupts the reconnection of lysed DNA. 18 Quinolones are divided into first, second, third, and fourth generations according to their discovery history and their antibacterial properties. At present, third-generation antibiotics are most commonly used in clinical practice. The types, structural changes, and characteristics of each generation of antibiotics are shown in Figure 2. In general, the further optimization or refinement of the synthesis approaches of drugs can enhance their bactericidal effects, but drug resistance may also occur after the structural modifications, which should be further investigated in the future study. Figure 2 Classification and features of quinolone antibiotics. Quinol -Abstract Truncated-

Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance

Multi-Targeting Exploration of New 2-Aminothiazolyl Quinolones: Synthesis, Antimicrobial Evaluation, Interaction with Dna, Combination with Topoisomerase Iv and Penetrability into Cells

Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria

Discovery of Benzimidazole–Quinolone Hybrids As New Cleaving Agents Toward Drug‐Resistant Pseudomonas Aeruginosa DNA

A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with Staphylococcus aureus DNA Gyrase

Mechanism of Quinolone Action and Resistance

Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance

Molecular mechanism of topoisomerase poisoning by the peptide antibiotic albicidin

Synthesis, evaluation, and CoMFA study of fluoroquinophenoxazine derivatives as bacterial topoisomerase IA inhibitors

Structural basis of quinolone derivatives, inhibition of type I and II topoisomerases and inquiry into the relevance of bioactivity in odd or even branches with molecular docking study

Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents

How Do Gepotidacin and Zoliflodacin Stabilize DNA Cleavage Complexes with Bacterial Type IIA Topoisomerases? 1. Experimental Definition of Metal Binding Sites

How do gepotidacin and zoliflodacin stabilize DNA-cleavage complexes with bacterial type IIA topoisomerases? 1. Experimental definition of metal binding sites

Experimental and Molecular Docking Studies of Cyclic Diphenyl Phosphonates as DNA Gyrase Inhibitors for Fluoroquinolone-Resistant Pathogens

Structural Basis of Transcription Inhibition by CBR Hydroxamidines and CBR Pyrazoles

Recognition of quinolone antibiotics by the multidrug efflux transporter MexB of Pseudomonas aeruginosa

Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria

Experimental localization of metal-binding sites reveals the role of metal ions in type II DNA topoisomerases

Quinolone Antibiotics: Resistance and Therapy

Design, Synthesis, and Evaluation of Novel Fluoroquinolone-Flavonoid Hybrids As Potent Antibiotics Against Drug-Resistant Microorganisms.

Breakage-Reunion Domain of Streptococcus Pneumoniae Topoisomerase IV: Crystal Structure of a Gram-Positive Quinolone Target